HUBBARD, Ohio, April 21 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX) -- NanoLogix Inc. has begun construction on a 2,800 square foot manufacturing facility at its headquarters in Hubbard, Ohio. It will contain a production cleanroom, cold-storage vault, and shipping and receiving area to be used in the fabrication of BNP(TM) Ultra-Fast test kits.
The revolutionary new BNP(TM) kits provide accelerated detection of bacteria and pathogens -- 100 to 600% faster than conventional Petri plate testing. They will have broad applications in Homeland Security, human and veterinary medicine, processing and safety of food, cosmetics and drugs, research and development, and industrial and environmental testing.
One of the foremost bio-defense and biomedical research centers in the U.S. recently found in its tests that the BNP(TM) provided results up to four times faster than current Petri plate methods. Using the BNP(TM) they were able to view anthrax cultures in one-quarter of the time, and bubonic plague (Black Death) cultures in half of the time possible with the best traditional methods. The study appears in the current online issue of Letters in Applied Microbiology. Link to study:
The new facility will replace the company's current limited-production operation at its research and development laboratory in Cincinnati, boosting production capability to thousands of BNP(TM) kits per day. This provides the opportunity for expanded R&D of other NanoLogix products at the Cincinnati lab.
The BNP(TM) kit is based on NanoLogix's revolutionary sandwiched-membrane Petri technology. The company believes the BNP(TM) has a high potential of capturing a significant percentage of the annual multi-billion dollar Petri plate market in both the United States and internationally.
NanoLogix CEO Bret Barnhizer stated: "With the BNP(TM) kits, we believe we are on our way to establishing a new 'gold Standard' for microorganism detection that will have a revolutionary effect on medical testing, diagnosis and treatment. This production facility will enable us to capitalize on our technology and provide product to those who are rapidly becoming aware of the BNP(TM) potential".
The test kits provide users the ability for faster detection of a long list of pathogens, including E-coli, Salmonella, Listeria, Enterobacter, Staphylococcus, Anthrax and Bubonic plague.
In addition to providing ultra-fast viewing of microorganisms normally cultured on standard Petri plates, the BNP(TM) kits can be used to assist in early detection of some of the most dangerous pathogens in the world, including those that pose significant potential threats for use as bio-weapons by terrorists.
The BNP(TM) production operation is expected to create a dozen jobs in the economically depressed Youngstown, Ohio, area, with more to follow as product demand increases.
Other NNLX News:
NanoLogix recently received a substantial royalty payment for 2008 from NutraPharma, a bio-pharmaceutical company with a license on a number of NanoLogix patents.
CEO Bret Barnhizer and Director John Chatterton recently met with U.S. Representative Tim Ryan (Ohio 17th District) in Washington DC for a discussion of Federal programs related to business assistance.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at: www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact: NanoLogix, Inc. Investor Relations Carol Surrena Telephone: 330-534-0800 E-mail: email@example.com
|SOURCE NanoLogix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved